Laboratorios Farmaceuticos Rovi, S.A.

DB:41L Stock Report

Market Cap: €3.2b

Laboratorios Farmaceuticos Rovi Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Juan Lopez-Belmonte Encina

Chief executive officer

€1.3m

Total compensation

CEO salary percentage55.2%
CEO tenure17.9yrs
CEO ownershipn/a
Management average tenureno data
Board average tenure5.6yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Juan Lopez-Belmonte Encina's remuneration changed compared to Laboratorios Farmaceuticos Rovi's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

€165m

Jun 30 2024n/an/a

€148m

Mar 31 2024n/an/a

€138m

Dec 31 2023€1m€743k

€170m

Sep 30 2023n/an/a

€197m

Jun 30 2023n/an/a

€186m

Mar 31 2023n/an/a

€194m

Dec 31 2022€1m€728k

€200m

Sep 30 2022n/an/a

€176m

Jun 30 2022n/an/a

€183m

Mar 31 2022n/an/a

€182m

Dec 31 2021€2m€327k

€153m

Sep 30 2021n/an/a

€113m

Jun 30 2021n/an/a

€82m

Mar 31 2021n/an/a

€71m

Dec 31 2020€561k€330k

€61m

Sep 30 2020n/an/a

€55m

Jun 30 2020n/an/a

€53m

Mar 31 2020n/an/a

€46m

Dec 31 2019€541k€320k

€39m

Sep 30 2019n/an/a

€33m

Jun 30 2019n/an/a

€27m

Mar 31 2019n/an/a

€18m

Dec 31 2018€908k€312k

€18m

Sep 30 2018n/an/a

€16m

Jun 30 2018n/an/a

€9m

Mar 31 2018n/an/a

€18m

Dec 31 2017€524k€303k

€17m

Compensation vs Market: Juan's total compensation ($USD1.41M) is about average for companies of similar size in the German market ($USD1.95M).

Compensation vs Earnings: Juan's compensation has been consistent with company performance over the past year.

CEO

Juan Lopez-Belmonte Encina

17.9yrs

Tenure

€1,346,000

Compensation

Mr. Juan Lopez-Belmonte Encina has been Chief Executive Officer of Laboratorios Farmaceuticos ROVI, S.A. since October 2007 and served as its President from October 2020 to October 2022. He has been with L...

Board Members

NamePositionTenureCompensationOwnership
Juan Lopez-Belmonte Encina
Chairman & CEO17.4yrs€1.35mno data
Ivan Lopez-Belmonte Encina
Second Deputy Chairman & GM of Commercial and Development17.4yrs€552.00kno data
Javier Lopez-Belmonte Encina
First Deputy Chairman17.4yrs€554.00kno data
Marcos Pena Pinto
Independent Director5.6yrs€80.00kno data
Fatima Garcia
Independent Director5yrs€80.00kno data
Marina del Tellez
Director2.6yrs€80.00kno data
Teresa Santamaria
Independent Director2yrs€80.00kno data

5.6yrs

Average Tenure

Experienced Board: 41L's board of directors are considered experienced (5.6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/18 15:41
End of Day Share Price 2024/12/18 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Laboratorios Farmaceuticos Rovi, S.A. is covered by 18 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Álvaro Arístegui EchevarríaAhorro Corporación
Guilherme SampaioBanco BPI, S.A.
Javier Esteban LarioBanco de Sabadell. S.A.